News / Taiwan / cnyes
Handa Pharma Surges Over 6% After Patent Lawsuit Dismissed in US
Health Technology · Biotechnology · cnyes · 2026-09-02
6620
Handa Pharma's stock rallied after the original manufacturer dropped a patent infringement lawsuit against its cancer drug HND-039, with expectations of FDA approval this quarter.
What Happened
Lawsuit Resolved: Handa Pharma (6620-TW) saw a significant legal hurdle cleared as the original manufacturer, Exelisis, dropped its patent infringement lawsuit against Handa's multi-target cancer drug, HND-039. This development removes a major uncertainty regarding the product's commercialization path in the United States.
Approval Outlook: Having secured Tentative Approval (TA) in July, Handa is awaiting final FDA approval, which analysts expect to arrive this quarter. The company is preparing for a potential US market launch in the fourth quarter, either through self-distribution or strategic partnerships.
Market Performance: Shares of Handa responded positively to the news, climbing over 6.8% during intraday trading to reach a high of 93.8 TWD. The stock successfully reclaimed its annual moving average on increased trading volume, reflecting strong investor confidence.
Pipeline Expansion: Beyond HND-039, Handa is actively pursuing 505(b)(2) regulatory filings for three additional drugs, including two oncology treatments and one neurological medication. These filings are scheduled for submission over the next two years as part of the company's long-term growth strategy.